M. Ignatiadis

3.2k total citations
6 papers, 27 citations indexed

About

M. Ignatiadis is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Ignatiadis has authored 6 papers receiving a total of 27 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Cancer Research and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Ignatiadis's work include HER2/EGFR in Cancer Research (2 papers), Cancer Genomics and Diagnostics (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). M. Ignatiadis is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Cancer Genomics and Diagnostics (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). M. Ignatiadis collaborates with scholars based in Belgium, France and Italy. M. Ignatiadis's co-authors include Stella Dolci, L. Vamvakas, N. Vardakis, Evandro de Azambuja, Kostas Kalbakis, Christos Sotiriou, Martine Piccart, Sofia Agelaki, Carolyn Straehle and K. Vantongelen and has published in prestigious journals such as Cancer Research, Critical Care Medicine and Annals of Oncology.

In The Last Decade

M. Ignatiadis

5 papers receiving 26 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Ignatiadis Belgium	4	17	11	7	7	5	6	27
Fernando Contreras Mejía Colombia	4	20 1.2×	4 0.4×	9 1.3×	4 0.6×	3 0.6×	13	47
Saad Tahir United Kingdom	4	23 1.4×	5 0.5×	3 0.4×	10 1.4×	3 0.6×	4	29
Alain Gratet France	3	23 1.4×	9 0.8×	9 1.3×	16 2.3×	5 1.0×	7	43
Abraham Tzou United States	1	13 0.8×	10 0.9×	3 0.4×	6 0.9×	6 1.2×	2	26
Fatemeh Allah Bakeshei Iran	4	13 0.8×	6 0.5×	11 1.6×	3 0.4×	3 0.6×	6	36
J. Maxwell Douglas Canada	3	11 0.6×	12 1.1×	4 0.6×	8 1.1×	4 0.8×	3	29
Zhanyu Pan China	4	20 1.2×	9 0.8×	2 0.3×	14 2.0×	3 0.6×	6	34
Brenda Hernandez Spain	2	15 0.9×	9 0.8×	11 1.6×	3 0.4×	6 1.2×	2	44
Reyes Gonzalez-Exposito Spain	4	19 1.1×	7 0.6×	8 1.1×	10 1.4×	6 1.2×	4	43
Corinna Slawinski United Kingdom	2	29 1.7×	7 0.6×	7 1.0×	9 1.3×	3 0.6×	4	45

Countries citing papers authored by M. Ignatiadis

Since Specialization

Citations

This map shows the geographic impact of M. Ignatiadis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ignatiadis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ignatiadis more than expected).

Fields of papers citing papers by M. Ignatiadis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ignatiadis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ignatiadis. The network helps show where M. Ignatiadis may publish in the future.

Co-authorship network of co-authors of M. Ignatiadis

This figure shows the co-authorship network connecting the top 25 collaborators of M. Ignatiadis. A scholar is included among the top collaborators of M. Ignatiadis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ignatiadis. M. Ignatiadis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Chanzá, Nieves Martínez, Philippe Barthélémy, Brieuc Sautois, et al.. (2021). 659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). Annals of Oncology. 32. S683–S683. 5 indexed citations

2.

Ignatiadis, M., Roberto Salgado, Marco Fornili, et al.. (2018). Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy. European Journal of Cancer. 92. S15–S15. 8 indexed citations

3.

Koch, Julian, Volkmar Müller, Tanja Fehm, et al.. (2014). Die TREAT-CTC-Studie (EORTC 90091 – 10093/BIG 1 – 12) – ein neuer Ansatz zur Therapie von zirkulierenden Tumorzellen (CTCs) beim frühen Mammakarzinom. Senologie - Zeitschrift für Mammadiagnostik und -therapie. 11(2). 1 indexed citations

4.

Peccatori, Fedro A., Sherene Loi, Diether Lambrechts, et al.. (2012). Abstract P6-07-14: Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome. Cancer Research. 72(24_Supplement). P6–7.

5.

Straehle, Carolyn, Fátima Cardoso, Evandro de Azambuja, et al.. (2008). Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer. Critical Care Medicine. 37(Supplement). S22–S29. 6 indexed citations

6.

Kalykaki, A., L. Vamvakas, Sofia Agelaki, et al.. (2006). A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors. Oncology. 71(3-4). 197–203. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact